{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-024346","form_type":"8-K","ticker":"EYPT","cik":"0001314102","company_name":"EyePoint, Inc.","filed_at":"2024-03-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.732501+00:00","generated_at":"2026-06-05T04:36:50.963525+00:00","sec_items":["8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"EyePoint names Ramiro Ribeiro as Chief Medical Officer, replaces Dario Paggiarino","bullets":["Ramiro Ribeiro appointed CMO effective March 1, 2024; succeeds Dario Paggiarino who leaves March 31.","Ribeiro joins from Apellis, where he led global Phase 3 GA program and FDA approval of SYFOVRE.","Company on track to report Phase 2 PAVIA topline data for EYP-1901 in NPDR in Q2 2024.","Initiation of Phase 3 LUGANO trial for EYP-1901 in wet AMD expected in second half 2024.","Board granted 125,000 stock options as inducement award to Ribeiro under Nasdaq Rule 5635(c)(4)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-024346","json":"https://secwatch.observer/filing/0000950170-24-024346.json","markdown":"https://secwatch.observer/filing/0000950170-24-024346.md","text":"https://secwatch.observer/filing/0000950170-24-024346.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1314102/000095017024024346/0000950170-24-024346-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1314102/000095017024024346/eypt-20240304.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T04:36:50.963525+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}